Food use
Food-use source coverage is present in the current record.
The ingredient appears in food-oriented source coverage or allowed-use references, which makes food use easier to support than a context with no domain signal at all.
Inorganic sulfites and bisulfites (12) is restricted in cosmetic products under Annex III of the EU Cosmetics Regulation (EC) 1223/2009.
Concern score
The concern value reflects this ingredient's chemical identity — its hazard profile from the published classifications and regulatory status below — not the safety of a product it appears in. A score near 40 is the baseline for ingredients with no specific signal (water scores 40 by design), so a mid-range value is not a safety verdict.
Concern score 70/100 (high) · high confidence.
Regional restrictions
Prevalence of SODIUM METABISULFITE in our catalog (epa_cpdat).
Products
981
Brands
6
Typical roles
Catalog
Context-specific fit derived from published classifications and the current ingredient evidence profile.
Food use
Food-use source coverage is present in the current record.
The ingredient appears in food-oriented source coverage or allowed-use references, which makes food use easier to support than a context with no domain signal at all.
Fragrance avoidance
Not a strong fit for fragrance avoidance because it carries Fragrance.
Canonical allergen markers detected on this ingredient. Each row is derived from the ingredient’s name or synonyms matching a known allergen class — useful when scanning a label for a specific allergy context.
Source: chemindex_name_match
Primary documents currently linked to this ingredient record.
Structured claim signals pulled from linked ingredient research.
Published jurisdiction-level classifications and regulatory designations for this ingredient.
EU
EC
Annex III of EU Cosmetics Regulation (EC) 1223/2009: substances which cosmetic products must not contain except subject to the restrictions laid down. Product types: (a) Oxidative hair dye products (b) Hair straightening products (c) Self-tanning products for the face (d) Other self-tanning products Maximum concentration: (a) 0.67% (as free SO2) (b) 6.7% (as free SO2) (c) 0.45% (as free SO2) (d) 0.40% (as free SO2) Other conditions: For purposes other than inhibiting the development of micro-organisms in the product. This purpose has to be apparent from the presentation of the product
EU
EC
Annex V of EU Cosmetics Regulation (EC) 1223/2009: preservatives allowed in cosmetic products. Maximum concentration: 0.2% (as free SO2)
Crème pour le corps Rice milk & cherry blossom
Rituals
The ingredient itself is a fragrance-linked signal, so it is better treated as an avoid case when fragrance exposure is the main concern.
The published evidence profile currently shaping this ingredient record.
US
EPA
EPA CPDat observed this chemical in 981 composition records across product categories including Laboratory supplies, Specialty occupational products, Batteries. EPA CPDat classifies this chemical for functional uses including Stabilizing agent, Preservative, Antioxidant.
US
FDA
Route: EPIDURAL; Dosage form: INJECTION; Potency: 0.05 %w/v
US
FDA
Route: INFILTRATION; Dosage form: INJECTION; Potency: 0.5 %w/v
US
FDA
Route: INFILTRATION; Dosage form: INJECTION, SOLUTION; Potency: 0.05 %w/v
US
FDA
Route: INTRA-ARTICULAR; Dosage form: INJECTION; Potency: 0.2 %w/v
US
FDA
Route: INTRABURSAL; Dosage form: INJECTION; Potency: 0.2 %w/v
US
FDA
Route: INTRACARDIAC; Dosage form: INJECTION; Potency: 0.09 %w/v
US
FDA
Route: INTRALESIONAL; Dosage form: INJECTION; Potency: 0.1 %w/v
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION; Potency: 27.5 %w/v
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, SOLUTION; Maximum daily exposure: 96 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, SOLUTION, CONCENTRATE; Potency: 0.15 %w/v
US
FDA
Route: INTRAOCULAR; Dosage form: INJECTION, SOLUTION, CONCENTRATE; Potency: 0.15 %w/v
US
FDA
Route: INTRAPERITONEAL; Dosage form: INJECTION; Potency: 0.33 %w/v
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION; Potency: 27.5 %w/v
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, EMULSION; Potency: 0.03 %w/v
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, SOLUTION; Maximum daily exposure: 79 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, SOLUTION, CONCENTRATE; Potency: 0.15 %w/v
US
FDA
Route: IONTOPHORESIS; Dosage form: SOLUTION; Potency: 0.05 %w/v
US
FDA
Route: IONTOPHORESIS; Dosage form: SYSTEM; Potency: 0.5 mg
US
FDA
Route: OPHTHALMIC; Dosage form: SOLUTION; Potency: 0.2 %w/w
US
FDA
Route: OPHTHALMIC; Dosage form: SUSPENSION/ DROPS; Potency: 0.1 %w/w
US
FDA
Route: ORAL; Dosage form: CONCENTRATE; Potency: 2 mg/1ml
US
FDA
Route: ORAL; Dosage form: SOLUTION; Maximum daily exposure: 640 mg
US
FDA
Route: ORAL; Dosage form: SUSPENSION; Maximum daily exposure: 40 mg
US
FDA
Route: ORAL; Dosage form: SUSPENSION, EXTENDED RELEASE; Maximum daily exposure: 100 mg
US
FDA
Route: ORAL; Dosage form: SYRUP; Maximum daily exposure: 80 mg
US
FDA
Route: ORAL; Dosage form: TABLET, CHEWABLE; Potency: 0.2 mg
US
FDA
Route: PERINEURAL; Dosage form: INJECTION; Potency: 0.05 %w/v
US
FDA
Route: RESPIRATORY (INHALATION); Dosage form: SOLUTION; Potency: 0.3 %w/w
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION; Maximum daily exposure: 43 mg
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, SOLUTION; Maximum daily exposure: 79 mg
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, SOLUTION, CONCENTRATE; Potency: 0.15 %w/v
US
FDA
Route: SUBMUCOSAL; Dosage form: INJECTION; Maximum daily exposure: 5 mg
US
FDA
Route: SUBMUCOSAL; Dosage form: INJECTION, SOLUTION; Potency: 5 %w/v
US
FDA
Route: TOPICAL; Dosage form: LOTION; Potency: 0.2 %w/v
US
FDA
Route: TOPICAL; Dosage form: SUSPENSION; Potency: 0.32 %w/v
US
FDA
openFDA substance registry classifies this ingredient as chemical.